BCAX

About Bicara Therapeutics Inc. Common Stock (BCAX) Stock

Bicara Therapeutics Inc. Common Stock (BCAX) closed the 2026-09-16 session at $22.00, down 2.96% versus the previous close (-0.67). The stock opened at $22.74 and traded between $21.86 and $23.25 during that session. Session trading volume was 798K shares. The volume-weighted average price (VWAP) is $22.33.

Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b. The company's goal is to build a fully integrated, commercial-stage biopharmaceutical company that develops important therapies for people living with cancer, starting with ficerafusp alfa.

Bicara Therapeutics Inc. Common Stock has a market capitalization of $1.46 billion. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. BCAX is listed on the XNAS exchange. The company employs approximately 103 people. Bicara Therapeutics Inc. Common Stock is headquartered in BOSTON, MA. The recorded listing date is 2024-09-13.

On this page you can find market BCAX stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.

Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.